» Articles » PMID: 23093347

Effects of a Single Injection of Teriparatide on Bone Turnover Markers in Postmenopausal Women

Overview
Journal Osteoporos Int
Date 2012 Oct 25
PMID 23093347
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: This study investigated the effects of a single administration of teriparatide on bone turnover markers in postmenopausal women. Teriparatide caused a transient increase in bone resorption and inhibition of bone formation followed by a subsequent increase in bone formation and a decrease in resorption that lasted at least 1 week.

Introduction: This study aims to investigate the effects of a single subcutaneous administration of teriparatide on bone turnover markers to elucidate why once weekly intermittent administration of teriparatide is effective on osteoporosis.

Methods: Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.

Results: Teriparatide plasma concentration increased in a dose-dependent manner, and the maximum concentration was achieved 1 h after injection. Serum levels of calcium and phosphorus were transiently increased and decreased after teriparatide injection, respectively. Calcium metabolism returned to baseline levels 24 h later. Two days after injection, the serum level of 1,25-dihydroxy vitamin D was increased by ~80 % from baseline for both doses of teriparatide. Serum levels of osteocalcin and procollagen type I N-terminal propeptide decreased during the first 24 h followed by a ~10 % increase for 14 days. The serum level of cross-linked N-telopeptide (NTX) of type I collagen increased during the first 24 h followed by a 10 to 12 % dose-dependent suppression from baseline for 14 days. Urinary cross-linked C-telopeptide of type I collagen changes occurred in the same direction as serum NTX, but not dose dependently.

Conclusion: A single administration of teriparatide caused an immediate, transient increase in bone resorption and inhibited bone formation followed by an increase in bone formation and decrease in resorption for ≥1 week. These findings may provide proof for the effect of a once-weekly regimen of teriparatide on bone turnover.

Citing Articles

Osteoporosis: Investigations and Monitoring.

Panchagnula R, Amarnath S Indian J Orthop. 2023; 57(Suppl 1):70-81.

PMID: 38107808 PMC: 10721590. DOI: 10.1007/s43465-023-01019-w.


Evaluation of cortical bone remodeling in canines treated with daily and weekly administrations of teriparatide by establishing AI-driven morphometric analyses and GIS-based spatial mapping.

Hoshi-Numahata M, Takakura A, Nakanishi-Kimura A, Watanabe H, Takada K, Nishiura M Bone Rep. 2023; 19:101720.

PMID: 37915737 PMC: 10616120. DOI: 10.1016/j.bonr.2023.101720.


Expansion of the osteocytic lacunar-canalicular system involved in pharmacological action of PTH revealed by AI-driven fluorescence morphometry in female rabbits.

Takakura A, Sato T, Lee J, Hirano K, Takao-Kawabata R, Ishizuya T Sci Rep. 2022; 12(1):16799.

PMID: 36207444 PMC: 9546928. DOI: 10.1038/s41598-022-20793-5.


Acute catabolic bone metabolism response to exercise in young and older adults: A narrative review.

Wherry S, Swanson C, Kohrt W Exp Gerontol. 2021; 157:111633.

PMID: 34826573 PMC: 10103539. DOI: 10.1016/j.exger.2021.111633.


Effect of weekly teriparatide injections on osteoporotic fracture healing: protocol for a double-blind, randomised controlled trial.

Zhu J, Zhang C, Jia J, Yuan W, Zhang M, Leng H BMJ Open. 2021; 11(4):e043137.

PMID: 33795297 PMC: 8021745. DOI: 10.1136/bmjopen-2020-043137.


References
1.
Crans G, Silverman S, Genant H, Glass E, Krege J . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis Rheum. 2004; 50(12):4028-34. DOI: 10.1002/art.20671. View

2.
Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D . Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20(6):962-70. DOI: 10.1359/JBMR.050105. View

3.
Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

4.
PAYNE R, Little A, Williams R, Milner J . Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893):643-6. PMC: 1587636. DOI: 10.1136/bmj.4.5893.643. View

5.
Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M . Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012; 97(9):3097-106. DOI: 10.1210/jc.2011-3479. View